Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932772 | 0.84 | ALB (0.47) | CES2CES1BCHESMN1; SMN2ALDH1A1 | |
| SCHEMBL29956608 | 0.82 | PARP1 (0.41) | CES2CES1BCHEALDH1A1HPGD | |
| SCHEMBL11303521 | 0.82 | CES2 (0.39) | CES2CES1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29954759 | 0.79 | TSHR (0.47) | KMT2AALDH1A1HPGDCA12CA1 | |
| SCHEMBL31419627 | 0.79 | MEN1 (0.43) | CES2CES1BCHEKMT2ASMN1; SMN2 | |
| SCHEMBL20530659 | 0.79 | TSHR (0.47) | KMT2AALDH1A1HPGDCA12CA1 | |
| SCHEMBL29957894 | 0.79 | MEN1 (0.43) | CES2CES1BCHEKMT2ASMN1; SMN2 | |
| SCHEMBL519802 | 0.79 | ENPP2 (0.41) | KMT2ASMN1; SMN2ALDH1A1PDK2CA12 | |
| SCHEMBL29469063 | 0.79 | ENPP2 (0.41) | KMT2ASMN1; SMN2ALDH1A1PDK2CA12 | |
| SCHEMBL25745449 | 0.78 | ENPP2 (0.42) | CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112062792-A | Production method of tris (dimethylamine) cyclopentadiene hafnium | 芯越芯(南京)电子科技有限公司 | 2020-12-11 | — | — | CN | claimed |
| CN-108148089-B | Preparation method of tetra (dimethylamino) titanium | 浙江博瑞电子科技有限公司 | 2020-09-08 | — | — | CN | claimed |
| US-20260135164-A1 | LITHIUM SECONDARY BATTERIES CAPABLE OF SELF-POISONING | PROLOGIUM TECHNOLOGY CO., LTD. (TW) | 2026-05-14 | — | — | US | disclosed |
| EP-4668366-A1 | LITHIUM SECONDARY BATTERY CAPABLE OF SELF-POISONING | Prologium Technology Co., Ltd. (TW) | 2025-12-24 | — | — | EP | disclosed |
| CN-119998964-A | Self-poisoning lithium secondary battery | 辉能科技股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024169769-A1 | LITHIUM SECONDARY BATTERY CAPABLE OF SELF-POISONING | 辉能科技股份有限公司 | 2024-08-22 | — | — | WO | disclosed |
| CN-112062792-A | Production method of tris (dimethylamine) cyclopentadiene hafnium | 芯越芯(南京)电子科技有限公司 | 2020-12-11 | — | — | CN | disclosed |
| CN-108148089-B | Preparation method of tetra (dimethylamino) titanium | 浙江博瑞电子科技有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-20190218215-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| EP-2858990-B1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | ABBVIE INC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9561231-B2 | Pyridinone and pyridazinone derivatives | ABBVIE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2274297-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-2264017-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| US-7498337-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260135164-A1 | LITHIUM SECONDARY BATTERIES CAPABLE OF SELF-POISONING | L3MBTL3, HAO2, LDHB | CES2 3117/4885CES1 4462/4885BCHE 177/4885 |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | HRH2, VIP, CCKBR | CES2 1439/4885CES1 104/4885BCHE 387/4885 |
| US-20190218215-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP28, USP1 | CES2 1049/4885CES1 547/4885BCHE 1743/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | CES2 2323/4885CES1 1069/4885BCHE 2642/4885 |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | HRH2, ASNS, GHSR | CES2 1276/4885CES1 73/4885BCHE 423/4885 |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | HRH2, GIPR, HRH4 | CES2 3007/4885CES1 355/4885BCHE 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.